Zai Lab Announces Publication From China's Gynecology Oncology Field In 'Cell'; Study Highlights Niraparib's Effect On Ovarian Cancer Microenvironment Stratified By HRD And Its Perturbation By PARP Inhibitor; Data Suggest Combination Of Niraparib And Investigational CCR8 Antibody ZL-1218 May Decrease Tumor Burden
Manuscript represents the first publication from China's gynecology oncology field to be published in Cell
Publication highlights first-time learnings about the landscape of ovarian cancer microenvironment stratified by HRD and how a PARP inhibitor perturbs it
Data suggest combination of niraparib and ZL-1218, an investigational CCR8 antibody, may decrease tumor burden, offering synergistic potential for improving efficacy in treatment of HRD tumors
Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688))))) today announced that data published in the journal Celldemonstrate that neoadjuvant monotherapy with the poly (ADP-ribose) polymerase (PARP) inhibitor niraparib results in a high response rate and reshapes the tumor microenvironment (TME), providing new targets for immunotherapy and combination regimens in patients with homologous recombination deficiency (HRD) positive ovarian cancer. The study revealed niraparib preferentially suppresses certain immune cells that support the growth of HRD-positive ovarian tumors.
This Zai Lab-supported study also showed that targeted clearance of infiltrating regulatory T cells (eTregs) using Zai Lab's investigational CCR8 antibody, ZL-1218, significantly sensitized niraparib against HRD tumors, resulting in decreased tumor burden in pre-clinical models.